우리나라의 다제약제 현황과 적정관리 방안에 대한 고찰
Reviews on the Current Status and Appropriate Management of Polypharmacy in South Korea
2
조회
0
다운로드
19
인용
0
참고문헌
키워드
초록
Polypharmacy is increasing owing to an increase in the elderly population and multimorbidities associated with the increased risk of administration of potentially inappropriate medications (PIMs). The negative effects of polypharmacy on various health conditions and aspects, such as fall, fracture, mortality, cognitive function, and dementia, have been reported. The management of excess and inappropriate polypharmacy through proper interventions and local or national guidelines has been highlighted. The purpose of polypharmacy management is to appropriately prescribe medicines that are essential to treat diseases in patients and to avoid inappropriate polypharmacy, such as interactive or duplicate medicines under prescription and PIMs for specific diseases. Community pharmacists in Australia, the EU, USA, and Japan are collaborating with prescribers to review medications to ensure that the patients can be prescribed appropriate medications. The service cost is reimbursed by public or private insurers. A study in the United States has shown that even with medication review costs, the overall medication cost has reduced. In Korea, various projects such as Drug Utilization Review service and safe use of medicines have been conducted; however, no national guidelines or management measures have been established. It is necessary to implement a national long-term plan on polypharmacy management. Furthermore, a phased implementation plan is required. Shortly, active medication review services and education programs for healthcare professionals with the support of the government should be considered in Korea with reference to other countries in order to raise awareness of seriousness and risks of inappropriate polypharmacy.
Abstract
Polypharmacy is increasing owing to an increase in the elderly population and multimorbidities associated with the increased risk of administration of potentially inappropriate medications (PIMs). The negative effects of polypharmacy on various health conditions and aspects, such as fall, fracture, mortality, cognitive function, and dementia, have been reported. The management of excess and inappropriate polypharmacy through proper interventions and local or national guidelines has been highlighted. The purpose of polypharmacy management is to appropriately prescribe medicines that are essential to treat diseases in patients and to avoid inappropriate polypharmacy, such as interactive or duplicate medicines under prescription and PIMs for specific diseases. Community pharmacists in Australia, the EU, USA, and Japan are collaborating with prescribers to review medications to ensure that the patients can be prescribed appropriate medications. The service cost is reimbursed by public or private insurers. A study in the United States has shown that even with medication review costs, the overall medication cost has reduced. In Korea, various projects such as Drug Utilization Review service and safe use of medicines have been conducted; however, no national guidelines or management measures have been established. It is necessary to implement a national long-term plan on polypharmacy management. Furthermore, a phased implementation plan is required. Shortly, active medication review services and education programs for healthcare professionals with the support of the government should be considered in Korea with reference to other countries in order to raise awareness of seriousness and risks of inappropriate polypharmacy.
참고문헌 (52)
- Ageing and Health Technical Report Vol. 5: A Glossary of Terms for Community Health Care and Services for Older Persons, "World Health Organization", ~ (2004)
- Mortazavi SS, "Defining polypharmacy in the elderly: a systematic review protocol", BMJ Open, 6(3), pp.e010989~ (2016)[DOI]
- Herr M, "Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people", Pharmacoepidemiol Drug Saf, 24(6), pp.637~646 (2015)[DOI]
- Jyrkka J, "Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population", Pharmacoepidemiol Drug Saf, 20(5), pp.514~522 (2011)[DOI]
- Nobili A, "Potentially severe drug interactions in elderly outpatients: results of an observational study of an administrative prescription database", J Clin Pharm Ther, 34(4), pp.377~386 (2009)[DOI]
- Wang R, "Incidence and Effects of Polypharmacy on Clinical Outcome among Patients Aged 80+: A Five-Year Follow-Up Study", PLoS One, 10(11), pp.e0142123~ (2015)[DOI]
- Fried TR, "Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review", J Am Geriatr Soc, 62(12), pp.2261~2272 (2014)[DOI]
- Park HY, "The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea", PLoS One, 12(1), pp.e0169463~ (2017)[DOI]
- Park HY, "Association of Parkinsonism or Parkinson Disease with Polypharmacy in the Year Preceding Diagnosis: A Nested Case-Control Study in South Korea", Drug Saf (2017)
- Masnoon N, "What is polypharmacy? A systematic review of definitions", BMC Geriatr, 17(1), pp.230~ (2017)
- Kim HA, "Prevalence and predictors of polypharmacy among Korean elderly", PLoS One, 9(6), pp.e98043~ (2014)[DOI]
- Nam YS, "Prescription of potentially inappropriate medication in Korean older adults based on 2012 Beers Criteria: a cross-sectional population based study", BMC Geriatr, 16, pp.118~ (2016)[DOI]
- Park HY, "Prescribed drugs and polypharmacy in healthcare service users in South Korea: an analysis based on National Health Insurance Claims data", Int J Clin Pharmacol Ther, 54(5), pp.369~377 (2016)[DOI]
- McCracken R, "Associations between polypharmacy and treatment intensity for hypertension and diabetes: a cross-sectional study of nursing home patients in British Columbia, Canada", BMJ Open, 7(8), pp.e017430~ (2017)
- Saum KU, "Is Polypharmacy Associated with Frailty in Older People? Results From the ESTHER Cohort Study", J Am Geriatr Soc, 65(2), pp.e27~e32 (2017)[DOI]
- Moriarty F, "Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study", BMJ Open, 5(9), pp.e008656~ (2015)[DOI]
- Beer C, "Quality use of medicines and health outcomes among a cohort of community dwelling older men: an observational study", Br J Clin Pharmacol, 71(4), pp.592~599 (2011)[DOI]
- Franchi C, "Geographical differences in the prevalence of chronic polypharmacy in older people: eleven years of the EPIFARM-Elderly Project", Eur J Clin Pharmacol, 69(7), pp.1477~1483 (2013)
- Niikawa H, "Association between polypharmacy and cognitive impairment in an elderly Japanese population residing in an urban community", Geriatr Gerontol Int, 17(9), pp.1286~1293 (2017)[DOI]
- Sinnige J, "Inter-practice variation in polypharmacy prevalence amongst older patients in primary care", Pharmacoepidemiol Drug Saf, 25(9), pp.1033~1041 (2016)[DOI]
- Nishtala PS, "Temporal Trends in Polypharmacy and Hyperpolypharmacy in Older New Zealanders over a 9-Year Period: 2005-2013", Gerontology, 61(3), pp.195~202 (2015)[DOI]
- Lu WH, "Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: a retrospective cohort study", CMAJ, 187(4), pp.E130~E137 (2015)[DOI]
- Charlesworth CJ, "Polypharmacy Among Adults Aged 65 Years and Older in the United States: 1988-2010", J Gerontol A Biol Sci Med Sci, 70(8), pp.989~995 (2015)[DOI]
- 장일영, "2012년 개정판 Beers Criteria를 통한 노인 부적절 약물 처방 현황에 관한 연구", Annals of geriatric medicine and research, 17(3), pp.126~133 (2013), 대한노인병학회
- Kojima T, "Polypharmacy as a risk for fall occurrence in geriatric outpatients", Geriatr Gerontol Int, 12(3), pp.425~430 (2012)[DOI]
- Zia A, "The consumption of two or more fall risk-increasing drugs rather than polypharmacy is associated with falls", Geriatr Gerontol Int, 17(3), pp.463~470 (2017)[DOI]
- Thorell K, "Is use of fall risk-increasing drugs in an elderly population associated with an increased risk of hip fracture, after adjustment for multimorbidity level: a cohort study", BMC Geriatr, 14, pp.131~ (2014)[DOI]
- Laflamme L, "Type, number or both? A population-based matched case-control study on the risk of fall injuries among older people and number of medications beyond fallinducing drugs", PLoS One, 10(3), pp.e0123390~ (2015)
- Richardson K, "Variation over time in the association between polypharmacy and mortality in the older population", Drugs Aging, 28(7), pp.547~560 (2011)[DOI]
- Lai SW, "Association between polypharmacy and dementia in older people: a population-based case-control study in Taiwan", Geriatr Gerontol Int, 12(3), pp.491~498 (2012)[DOI]
- Aronson JK, "In defence of polypharmacy", Br J Clin Pharmacol, 57(2), pp.119~120 (2004)[DOI]
- Aronson JK, "Polypharmacy, appropriate and inappropriate", Br J Gen Pract, 56(528), pp.484~445 (2006)
- Cole A, "The importance of 'appropriate' polypharmacy and the value of medicines", European Journal of Hospital Pharmacy, 24(1), pp.70~72 (2017)
- Patterson SM, "Interventions to improve the appropriate use of polypharmacy for older people", Cochrane Database Syst Rev, 10 (2014)
- Oboh L, "Deprescribing and managing polypharmacy in frail older people: a patient-centred approach in the real world", European Journal of Hospital Pharmacy, 24(1), pp.58~62 (2017)[DOI]
- Cullinan S, "Challenges of deprescribing in the multimorbid patient", European Journal of Hospital Pharmacy, 24(1), pp.43~46 (2017)
- Kuijpers MA, "Relationship between polypharmacy and underprescribing", Br J Clin Pharmacol, 65(1), pp.130~133 (2008)[DOI]
- Levy HB, "Polypharmacy Reduction Strategies: Tips on Incorporating American Geriatrics Society Beers and Screening Tool of Older People's Prescriptions Criteria", Clin Geriatr Med, 33(2), pp.177~187 (2017)[DOI]
- Barnett N, "A themed journal issue on deprescribing", European Journal of Hospital Pharmacy, 24(1), pp.1~2 (2017)[DOI]
- Scott I, "Review of structured guides for deprescribing", European Journal of Hospital Pharmacy, 24(1), pp.51~57 (2017)[DOI]
- Bulajeva A, "Medication review practices in European countries", Res Social Adm Pharm, 10(5), pp.731~740 (2014)[DOI]
- A study on the pharmacy manpower project "Vision 2013"; A research report for the Ministry of Health and Welfare, "Kwon KH", ~ (2013)
- Mair A, "Polypharmacy management programmes: the SIMPATHY Project", European Journal of Hospital Pharmacy, 24(1), pp.5~6 (2017)[DOI]
- "Medication management reviews"[URL]
- Chen TF, "Pharmacist-Led Home Medicines Review and Residential Medication Management Review: The Australian Model", Drugs Aging, 33(3), pp.199~204 (2016)[DOI]
- Gilbert AL, "Collaborative medication management services: improving patient care", Med J Aust, 177(4), pp.189~192 (2002)
- Emblen G, "Home medicines review. The how and why for GPs", Aust Fam Physician, 33(1-2), pp.49~51 (2004)
- Dhillon AK, "General practitioners' perceptions on home medicines reviews: a qualitative analysis", BMC Fam Pract, 16, pp.16~ (2015)[DOI]
- Dolovich L, "Uptake of the MedsCheck annual medication review service in Ontario community pharmacies between 2007 and 2013", Canadian Pharmacists Journal, 149(5), pp.293~302 (2016)
- Barnett MJ, "Analysis of pharmacist-provided medication therapy management (MTM) services in community pharmacies over 7 years", J Manag Care Pharm, 15(1), pp.18~31 (2009)
- Matlin OS, "Community pharmacy automatic refill program improves adherence to maintenance therapy and reduces wasted medication", Am J Manag Care, 21(11), pp.785~791 (2015)
- "Drug Utilization Review; DUR system" (2017)[URL]